Structure Therapeutics Inc. (GPCR)
Automate Your Wheel Strategy on GPCR
With Tiblio's Option Bot, you can configure your own wheel strategy including GPCR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GPCR
- Rev/Share 0.0
- Book/Share 4.793
- PB 1.5036
- Debt/Equity 0.0092
- CurrentRatio 23.2856
- ROIC -0.2198
- MktCap 1243942719.0
- FreeCF/Share -0.7918
- PFCF -9.1314
- PE -8.6511
- Debt/Assets 0.0088
- DivYield 0
- ROE -0.1635
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | GPCR | Citigroup | -- | Buy | -- | $60 | May 2, 2025 |
| Initiation | GPCR | William Blair | -- | Outperform | -- | -- | Feb. 28, 2025 |
| Initiation | GPCR | Stifel | -- | Buy | -- | $50 | Jan. 8, 2025 |
| Initiation | GPCR | H.C. Wainwright | -- | Buy | -- | $80 | Dec. 4, 2024 |
| Initiation | GPCR | Morgan Stanley | -- | Overweight | -- | $118 | Sept. 23, 2024 |
News
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL.
Read More
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.
Read More
Why Structure Therapeutics Stock Was Stumbling This Week
Published: February 14, 2025 by: The Motley Fool
Sentiment: Negative
The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics (GPCR 0.16%), was a victim of a general rout in the segment.
Read More
About Structure Therapeutics Inc. (GPCR)
- IPO Date 2023-02-03
- Website https://structuretx.com
- Industry Biotechnology
- CEO Dr. Raymond C. Stevens Ph.D.
- Employees 163